Enhertu offers survival benefits in Phase II solid tumour trial

Enhertu offers survival benefits in Phase II solid tumour trial

Submitted by admin on July 29, 2023 - 10:42pm
Source: 
Clinical Trials Arena
News Tags: 
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
solid tumors
Headline: 
Enhertu offers survival benefits in Phase II solid tumour trial
snippet: 

AstraZeneca–Daiichi Sankyo have reported data from the Phase II DESTINY-PanTumor02 clinical trial, where Enhertu (trastuzumab deruxtecan) showed offering survival benefits in patients with HER2-expressing advanced solid tumors.

Do Not Allow Advertisers to Use My Personal information